Related Experiment Video

Updated: May 12, 2026

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
05:17

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing

Published on: October 10, 2025

Targeted agents in non-small cell lung cancer therapy: What is there on the horizon?

Victoria M Villaflor1, Ravi Salgia

  • 1Department of Medicine, Section of Hematology/Oncology University of Chicago, Chicago, IL, USA.

Journal of Carcinogenesis
|April 20, 2013
PubMed

Insights

This review covers current and emerging molecular targets for personalized lung cancer treatment, including epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF). It also addresses challenges like therapy resistance.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Lung cancer is a complex disease with significant research advancements in personalized treatment approaches over the last decade.
  • Understanding molecular heterogeneity is crucial for effective lung cancer management.

Purpose of the Study:

  • To review current literature on molecular targets for lung cancer therapy.
  • To provide an overview of established and emerging therapeutic targets.
  • To discuss challenges related to targeted therapy resistance.

Main Methods:

  • Literature review of scientific publications.
  • Synthesis of information on molecular targets and associated therapies.
  • Analysis of resistance mechanisms in targeted lung cancer treatments.

Main Results:

  • Identified key molecular targets including epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF), anaplastic large-cell lymphoma kinase (ALK), KRAS, C-MET/RON, PIK3CA, ROS-1, RET, Fibroblast growth factor receptor (FGFR), and Ephrins.
  • Highlighted the availability of therapies for some targets and the potential for others.
  • Discussed the issue of resistance to targeted therapies.

Conclusions:

  • Personalized medicine in lung cancer has advanced significantly due to research into molecular targets.
  • Ongoing research continues to identify new targets and therapeutic strategies.
  • Addressing resistance mechanisms is critical for improving long-term patient outcomes.
Keywords:
Cellular mechanismHGFMEToncogenereceptor tyrosine kinasetargeted cancer therapy

More Related Videos

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer07:59

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles08:03

Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles

Published on: December 1, 2016

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.